All HCA (n = 47) | H-HCA (n = 13) | b-HCA (n = 7) | I-HCA (n = 27) | P value | |
---|---|---|---|---|---|
Women (%) | 43 (92) | 12 (92) | 5 (71) | 26 (96) | .11 |
Age (years) ± SD (range) | 35 ± 7 (18–57) | 37 ± 8 (18–57) | 32 ± 8 (22–51) | 35 ± 6 (24–47) | .38 |
BMI (kg/m2) ± SD | 26 ± 3 | 24 ± 2 | 25 ± 2 | 27 ± 3 | .62 |
Oral estrogen intakea (%) | 23 (53) | 5 (42) | 3 (60) | 15 (58) | .56 |
Previous pregnancya (%) | 13 (30) | 7 (58) | 0 (0) | 6 (23) | .03 |
Menopausea (%) | 1 (2) | 1 (8) | 0 (0) | 0 (0) | .27 |
Metabolic syndrome (%) | 5 (11) | 1 (8) | 0 (0) | 4 (15) | .56 |
Days between MRI and histology ± SD (range) | 43 ± 25 (0–90) | 43 ± 30 (0–90) | 60 ± 21 (2–90) | 39 ± 25 (0–89) | .28 |
Lesion size (mm) ± SD (range) | 58 ± 25 (20–143) | 60 ± 20 (25–143) | 73 ± 29 (38–125) | 54 ± 25 (20–140) | .21 |
Surgical resection (%) | 14 (30) | 2 (15) | 5 (72) | 7 (26) | .03 |
Presence of hepatic steatosis (%)b | 16 (34) | 1 (8) | 1 (14) | 14 (52) | .01 |
Presence of intralesional fat (%)b | 17 (36) | 12 (92) | 4 (57) | 1 (4) | < .001 |
MRI features (%) | |||||
Arterial phase | |||||
Hyperintense | 38 (81) | 8 (62) | 5 (71) | 25 (93) | .05 |
Isointense | 7 (15) | 4 (31) | 1 (14) | 2 (7) | .15 |
Hypointense | 2 (4) | 1 (8) | 1 (14) | 0 (0) | .42 |
Portal venous phase | |||||
Hyperintense | 24 (51) | 0 (0) | 1 (14) | 23 (85) | < .001 |
Isointense | 8 (17) | 2 (15) | 3 (43) | 3 (11) | .14 |
Hypointense | 15 (32) | 11 (85) | 3 (43) | 1 (4) | < .001 |
Delayed phase | |||||
Hyperintense | 22 (47) | 0 (0) | 1 (14) | 21 (78) | < .001 |
Isointense | 6 (13) | 0 (0) | 2 (29) | 4 (15) | .33 |
Hypointense | 19 (40) | 13 (100) | 4 (57) | 2 (7) | < .001 |
T2-weighted | |||||
Hyperintense | 23 (49) | 1 (8) | 5 (71) | 17 (63) | .001 |
Isointense | 16 (34) | 7 (54) | 2 (29) | 7 (26) | .21 |
Hypointense | 8 (17) | 5 (39) | 0 (0) | 3 (11) | .10 |
Out-of-phase sequence signal drop | 15 (32) | 10 (77) | 3 (43) | 2 (7) | < .001 |